Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quercus ilex and Quercus robur allergen extracts HEP determination
2024-515189-14-00Phase 2Completed
- Sponsor
- Inmunotek
- Start
- Oct 2024
- Modality
- Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Quercus ilex pollen allergen extract and quercus robur pollen extract in allergic rhinoconjunctivitis (ARC), allergic asthma, Holm oak pollen allergy and 1 more, sponsored by Inmunotek. Primary endpoint: Skin papule size for each concentration of allergenic extracts and controls. Started Oct 2024; status: completed.
02
Drugs
Quercus ilex pollen allergen extractquercus robur pollen extract
03
Conditions
allergic rhinoconjunctivitis (ARC)allergic asthmaHolm oak pollen allergyQuercus robur pollen allergy
Beyond the preview
Go deeper on 2024-515189-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515189-14-00.